MedTrace Logo

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

NCT00226915 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 637

Last updated 2020-02-17

No results posted yet for this study

Summary

The purpose of the study is to compare progression-free survival of conventional paclitaxel and carboplatin vs weekly paclitaxel and carboplatin in patients with newly diagnosed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Conditions

Interventions

DRUG

Paclitaxel+Carboplatin

Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles

DRUG

Paclitaxel+Carboplatin

Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles

Sponsors & Collaborators

  • Japanese Gynecologic Oncology Group

    lead OTHER

Principal Investigators

  • Makoto Yasuda, M.D. · The Jikei University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226915 on ClinicalTrials.gov